A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how patient monitoring sto...
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulator...
iRhythm’s stock price has taken a beating over the past six months, shedding 27.5% of its value and falling to $115.17 per share. This may have investors won...
iRhythm’s second quarter results were met with a strong positive market reaction, reflecting the company’s ability to deliver both robust revenue growth and ...
What Happened? Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) fell 2.8% in the afternoon session after a significant price target cu...
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
What Happened? Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong s...
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 20.1% yea...
iRhythm Technologies (NASDAQ:IRTC) reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets.
Revenue for the quarter ended at $2
Medical technology company iRhythm Technologies (NASDAQ:IRTC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224....
Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be reporting results this Thursday after market hours. Here’s what to look for. iRhythm be...
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial ...
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
iRhythm’s stock price has taken a beating over the past six months, shedding 37.6% of its value and falling to $114.01 per share. This may have investors won...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
iRhythm Technologies (NASDAQ:IRTC) executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on several product and margin initiatives.
Speaking at an investor event, Stephanie Zhadkevich, senior
